What Is TB-500?
TB-500 is a synthetic 17-amino acid peptide corresponding to the actin-binding domain of Thymosin Beta-4 (Tβ4), a highly conserved 43-amino acid protein found at elevated concentrations in blood platelets and wound fluid. CAS 77591-33-4. The fragment retains the functional actin-sequestering capacity of the full-length protein while providing a more chemically defined tool for laboratory research than the intact, post-translationally modified parent molecule.
Thymosin Beta-4 itself is encoded by the TMSB4X gene and plays essential roles in cytoskeletal organization, cell motility, and developmental biology. The TB-500 fragment, which spans residues 17–23 of the full protein, isolates the G-actin binding activity responsible for most of the biological effects attributed to Tβ4 in published research. TB-500 is available from Lone Star Peptide Co. as a lyophilized powder verified at ≥99% HPLC purity.
Actin Polymerization and Cytoskeletal Dynamics
The primary biochemical function of TB-500 in research models is G-actin sequestration. By binding monomeric (globular) actin, TB-500 influences the equilibrium between G-actin and F-actin (filamentous actin), effectively modulating the rate and extent of actin polymerization in a concentration-dependent manner. This makes TB-500 a powerful tool for studying cytoskeletal dynamics in cell biology research.
Actin dynamics govern a broad range of cellular processes, cell division, migration, adhesion, and shape change all depend on tightly regulated cycles of polymerization and depolymerization. By artificially modulating G-actin availability, TB-500 provides researchers with a pharmacological handle on these processes that is mechanistically distinct from cytochalasin- or phalloidin-based interventions.
TB-500 acts as a G-actin sequestrant, it binds monomeric actin and prevents incorporation into filaments. This is mechanistically distinct from cytochalasin D (which caps barbed ends) and latrunculin (which also sequesters G-actin but at a different binding site). TB-500's binding epitope and downstream effects on filament nucleation differ sufficiently to warrant independent characterization in any research system where actin dynamics are the endpoint.
Cell Migration Research
Cell migration is among the most well-documented downstream readouts of TB-500 activity. Published studies in multiple cell types, including endothelial cells, keratinocytes, and cardiac myocytes, report enhanced migration rates following TB-500 treatment. The mechanism is attributed to reorganization of the actin cytoskeleton in a manner that promotes lamellipodia formation and directional motility.
For researchers designing wound healing assays, scratch assays (wound closure models), or transwell migration experiments, TB-500 provides a well-characterized pro-migratory stimulus. Published dose-response data across multiple cell lines is available in the primary literature, providing a framework for experimental design in new cell type contexts.
Angiogenesis and Endothelial Biology
TB-500 has been studied in the context of angiogenesis: the formation of new blood vessels from existing vasculature. Published work in endothelial cell models and rodent model systems documents TB-500-induced upregulation of VEGF and its receptor VEGFR-2, enhanced tube formation in Matrigel assays, and increased microvessel density in implanted tissue models. The angiogenic activity appears to operate partially through the actin remodeling pathway and partially through direct growth factor signaling.
For researchers working in vascular biology, angiogenesis assays, or ischemia model systems, TB-500 represents a well-characterized pro-angiogenic tool with a distinct mechanism from VEGF protein itself. It can be used to study the cytoskeletal contribution to endothelial sprouting independently of growth factor receptor kinetics.
Combined Pathway Research with BPC-157
TB-500 and BPC-157 are mechanistically complementary compounds that are frequently studied in combination in tissue remodeling research. BPC-157 primarily modulates NO signaling and growth factor receptor pathways; TB-500 addresses the actin cytoskeleton and cell migration axis. Research hypothesizes that simultaneous activation of both pathways may produce additive or synergistic effects in tissue remodeling models compared to either compound alone.
The Wolverine Blend provides both compounds pre-formulated in a single vial for researchers investigating combined pathway effects. This approach is particularly relevant for experimental systems where both cytoskeletal reorganization (TB-500's domain) and angiogenic/NO signaling (BPC-157's domain) are expected to contribute to the observed biological response.
Storage and Laboratory Handling
TB-500 is supplied as a lyophilized white powder with good aqueous solubility in sterile water and PBS. Reconstitute by adding solvent gently along the vial wall without vortexing. For cell culture applications, sterile-filtered solvent is required. Store the lyophilized powder at −20°C, protected from moisture and light. Reconstituted solutions are stable at 4°C for up to 7 days; for longer storage, aliquot into single-use volumes at −20°C.
TB-500's peptide structure makes it susceptible to standard peptide degradation pathways, oxidation of methionine residues under oxidizing conditions, hydrolysis at aspartate-proline bonds under acidic conditions, and aggregation at elevated concentrations. Review our peptide storage mistakes guide to ensure compound integrity throughout your experimental workflow.
Frequently Asked Questions
FOR RESEARCH USE ONLY. All compounds referenced in this article are supplied exclusively for in vitro and laboratory research by qualified scientists. Not intended for human or animal consumption, therapeutic use, or clinical application. This article is provided for scientific and educational purposes only. Lone Star Peptide Co. makes no therapeutic claims regarding any compound referenced herein.